Circulating or cell-associated ncRNA signatures, particularly elevated miR-155, miR-21, and diminished GAS5 or miR-146a, have already shown promise as biomarkers that track disease activity across lupus, RA, and MS cohorts (18, 48, 49, 73). This evidence concerns the gene GAS5 and myeloid sarcoma.